Aqueous core epigallocatechin gallate PLGA nanocapsules: characterization, antibacterial activity against uropathogens, and in vivo reno-protective effect in cisplatin induced nephrotoxicity.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE

Publication: 2015->: Abingdon, Oxford : Taylor & Francis
Original Publication: Orlando, FL : Academic Press, c1993-

Nanocapsules*/chemistry ; Nanoparticles*/chemistry; Animals ; Anti-Bacterial Agents/pharmacology ; Catechin/analogs & derivatives ; Cisplatin ; Kidney ; Male ; Mice ; Particle Size ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry

Epigallocatechin-3-gallate (EGCG) was isolated from Cycas thouarsii leaves for the first time and encapsulated in aqueous core poly(lactide-co-glycolide) (PLGA) nanocapsules (NCs). This work investigates antimicrobial activity and in vivo reno-protective effects of EGCG-PLGA NCs in cisplatin-induced nephrotoxicity. A double emulsion solvent evaporation process was adopted to prepare PLGA NCs loaded with EGCG. Particle size, polydispersity index (PDI), zeta potential, percent entrapment efficiency (%EE), structural morphology, and in vitro release platform were all studied in vitro . The optimum formula (F2) with particle size (61.37 ± 5.90 nm), PDI (0.125 ± 0.027), zeta potential (-11.83 ± 3.22 mV), %EE (85.79 ± 5.89%w/w), initial burst (36.85 ± 4.79), and percent cumulative release (87.79 ± 9.84) was selected for further in vitro/in vivo studies. F2 exhibited an enhanced antimicrobial activity against uropathogens as it had lower minimum inhibitory concentration (MIC) values and a more significant impact on bacterial growth than free EGCG. Forty male adult mice were randomly allocated into five groups: control vehicle, untreated methotrexate, MTX groups treated with a daily oral dose of free EGCG, placebo PLGA NCs, and EGCG PLGA NCs (F2) for 10 days. Results showed that EGCG PLGA NCs (F2) exerted promising renoprotective effects compared to free EGCG. EGCG PLGA NCs group induced a significant decrease in kidney index, serum creatinine, kidney injury molecule-1 (KIM-1), NGAL serum levels, and pronounced inhibition of NLPR-3/caspase-1/IL/1β inflammasome pathway. It also significantly ameliorated oxidative stress and decreased NFκB, Bax expression levels. Aqueous core PLGA NCs are a promising formulation strategy that provides high polymeric protection and sustained release pattern for hydrophilic therapeutic agents.

Life Sci. 2010 Aug 14;87(7-8):240-5. (PMID: 20619277)
Pharmaceuticals (Basel). 2021 Aug 01;14(8):. (PMID: 34451853)
Int J Mol Med. 2012 May;29(5):946-56. (PMID: 22367622)
Int J Nanomedicine. 2020 Jun 19;15:4417-4429. (PMID: 32606686)
PLoS One. 2015 Apr 15;10(4):e0124775. (PMID: 25875356)
Int J Mol Sci. 2021 Jun 26;22(13):. (PMID: 34206850)
Molecules. 2019 Jun 06;24(11):. (PMID: 31174271)
Phytomedicine. 2020 Dec;79:153316. (PMID: 32942205)
Eur J Pharm Biopharm. 2015 Jan;89:30-9. (PMID: 25460850)
PLoS One. 2013 Nov 22;8(11):e79834. (PMID: 24278192)
Oxid Med Cell Longev. 2017;2017:3172692. (PMID: 28698767)
Inflammation. 2018 Jun;41(3):1032-1048. (PMID: 29500724)
Front Chem. 2020 Oct 23;8:573297. (PMID: 33195062)
Heliyon. 2019 Jul 03;5(7):e02020. (PMID: 31317081)
Mediators Inflamm. 2016;2016:5460302. (PMID: 27672241)
Nat Rev Microbiol. 2015 May;13(5):269-84. (PMID: 25853778)
Int J Nanomedicine. 2022 Mar 17;17:1203-1225. (PMID: 35330694)
Antioxidants (Basel). 2020 May 19;9(5):. (PMID: 32438698)
Int Immunopharmacol. 2018 Jan;54:125-130. (PMID: 29128856)
Int J Mol Sci. 2020 Jul 08;21(14):. (PMID: 32650482)
PLoS One. 2016 Feb 11;11(2):e0149032. (PMID: 26866373)
Antibiotics (Basel). 2021 Jul 22;10(8):. (PMID: 34438940)
Anticancer Agents Med Chem. 2006 Sep;6(5):389-406. (PMID: 17017850)
Gut Liver. 2012 Apr;6(2):188-96. (PMID: 22570747)
Antioxid Redox Signal. 2015 May 1;22(13):1111-29. (PMID: 25330206)
Food Chem. 2022 Jun 15;379:132135. (PMID: 35063850)
Int J Mol Sci. 2021 Mar 19;22(6):. (PMID: 33808935)
Biochem Biophys Res Commun. 2011 Oct 28;414(3):551-6. (PMID: 21982776)
World J Oncol. 2014 Jun;5(3):97-108. (PMID: 29147386)
Braz J Microbiol. 2021 Jun;52(2):927-937. (PMID: 33826115)
Toxicology. 2008 Jan 20;243(3):340-7. (PMID: 18069112)
Free Radic Biol Med. 2011 Aug 1;51(3):744-54. (PMID: 21641991)
Curr Opin Toxicol. 2020 Feb;19:112-120. (PMID: 32566805)
Macromol Biosci. 2021 Jul;21(7):e2100046. (PMID: 34117834)
PLoS One. 2015 Mar 18;10(3):e0119543. (PMID: 25785827)
Eur J Pharm Sci. 2018 Mar 1;114:372-384. (PMID: 29288081)
Sci Rep. 2016 Jul 25;6:30233. (PMID: 27452398)
Food Funct. 2021 Jun 21;12(12):5658-5667. (PMID: 34018522)
World J Gastroenterol. 2014 Jul 7;20(25):8082-91. (PMID: 25009380)
Kidney Int. 2008 May;73(9):994-1007. (PMID: 18272962)
Pharmaceutics. 2021 Oct 11;13(10):. (PMID: 34683951)
Nanomaterials (Basel). 2020 Jan 12;10(1):. (PMID: 31940900)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
BMC Complement Altern Med. 2019 Jun 13;19(1):129. (PMID: 31196040)
Nanomedicine. 2020 Feb;24:102125. (PMID: 31751769)
Molecules. 2019 Feb 22;24(4):. (PMID: 30813243)
Pharmaceuticals (Basel). 2022 Jan 31;15(2):. (PMID: 35215291)
Apoptosis. 2017 May;22(5):672-680. (PMID: 28317089)
J Appl Microbiol. 2022 Feb;132(2):949-963. (PMID: 34365707)
Oxid Med Cell Longev. 2020 Aug 27;2020:6092715. (PMID: 32908633)
Sci Rep. 2018 Oct 29;8(1):15922. (PMID: 30374107)

Keywords: Double emulsion/solvent evaporation; KIM-1; NLPR-3 inflammasome; Nrf-2; cisplatin; dual surfactant action; sustained-release

0 (Anti-Bacterial Agents)
0 (Nanocapsules)
1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
8R1V1STN48 (Catechin)
BQM438CTEL (epigallocatechin gallate)
Q20Q21Q62J (Cisplatin)

Date Created: 20220616 Date Completed: 20220620 Latest Revision: 20231031

20231215

PMC9225707

10.1080/10717544.2022.2083725

35708451